EGFR-tyrosine kinase inhibitors (TKIs) have been successfully developed for EGFR-mutated non-small cell lung cancer (NSCLC) and continue to stand as robust first-line treatments for advanced NSCLC harboring EGFR mutations [3–6]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.